Literature DB >> 10873110

Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.

S J Welsh1, J Titley, L Brunton, M Valenti, P Monaghan, A L Jackman, G W Aherne.   

Abstract

Thymidylate synthase (TS) is an important target for cancer chemotherapy. However, several mechanisms of resistance to TS inhibitors have been described. One mechanism that may be relevant to short-term exposure to TS inhibitors occurs as a result of disruption of the autoregulatory loop, which allows TS to control its own translation. This disruption leads to up-regulation of TS protein and is generally thought to decrease efficacy. This study has investigated TS protein up-regulation using a range of TS inhibitors in both tumor and nonmalignant cell lines in vitro and in vivo. Up-regulation of TS protein showed a time-, dose-, and cell-type-specific response to treatment with ZD9331. This response was observed in W1L2 cells treated for 24 h at equitoxic doses of raltitrexed (6-fold), ZD9331 (10-fold), fluorouracil (5-fold), LY231514 (7-fold), AG337 (7-fold), and BW1843U89 (3-fold). Up-regulation was observed over a range of doses. Elevation of TS protein only persisted up to 12 h after removal of drug. The extent of induction does not depend on basal TS levels. Nontransformed human fibroblasts showed significantly greater up-regulation of TS protein than tumor cells exposed to an equitoxic dose of ZD9331. In vivo experiments using the L5178Y thymidine kinase -/- mouse lymphoma implanted into DBA2 mice also showed greater up-regulation of TS protein in normal intestinal epithelial cells compared with tumor cells. These results confirm that TS up-regulation is a common feature of TS inhibition in tumor cells and that it may occur to a greater extent in normal tissues, although the clinical implications of these findings remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873110

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.

Authors:  Masafumi Ikeda; Izumi Ohno; Hideki Ueno; Shuichi Mitsunaga; Yusuke Hashimoto; Takuji Okusaka; Shunsuke Kondo; Mitsuhito Sasaki; Yasunari Sakamoto; Hideaki Takahashi; Rina Hara; Shingo Kobayashi; Osamu Nakamura; Chigusa Morizane
Journal:  Invest New Drugs       Date:  2018-07-11       Impact factor: 3.850

2.  Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Authors:  P J Ferguson; J M DeMoor; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 3.  Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-06-09

4.  Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.

Authors:  Minaxi Jhawer; Lee Rosen; Janet Dancey; Howard Hochster; Solomon Hamburg; Margaret Tempero; Neil Clendeninn; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-09-07       Impact factor: 3.850

5.  Human thymidylate synthase with loop 181-197 stabilized in an inactive conformation: ligand interactions, phosphorylation, and inhibition profiles.

Authors:  BeiBei Luo; Jayanthi Repalli; Al-Motassem Yousef; Saphronia R Johnson; Lukasz Lebioda; Sondra H Berger
Journal:  Protein Sci       Date:  2011-01       Impact factor: 6.725

6.  Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?

Authors:  Phuong Thu Vu Hoang; Jérôme Ambroise; Anne-France Dekairelle; Jean-François Durant; Valentina Butoescu; Vu Luan Dang Chi; Nghia Huynh; Tan Binh Nguyen; Annie Robert; Christiane Vermylen; Jean-Luc Gala
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 7.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

8.  Cancer cell adaptation to chemotherapy.

Authors:  Federica Di Nicolantonio; Stuart J Mercer; Louise A Knight; Francis G Gabriel; Pauline A Whitehouse; Sanjay Sharma; Augusta Fernando; Sharon Glaysher; Silvana Di Palma; Penny Johnson; Shaw S Somers; Simon Toh; Bernie Higgins; Alan Lamont; Tim Gulliford; Jeremy Hurren; Constantinos Yiangou; Ian A Cree
Journal:  BMC Cancer       Date:  2005-07-18       Impact factor: 4.430

9.  Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway.

Authors:  Kun-Chieh Chen; Tsung-Ying Yang; Chun-Chi Wu; Chi-Chih Cheng; Shih-Lan Hsu; Hsiao-Wen Hung; Jian-Wei Chen; Gee-Chen Chang
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

10.  Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells.

Authors:  Tsung-Ying Yang; Gee-Chen Chang; Shih-Lan Hsu; Yi-Rou Huang; Ling-Yen Chiu; Gwo-Tarng Sheu
Journal:  Biomed Res Int       Date:  2013-07-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.